DRG Epidemiology’s coverage of scleroderma (systemic sclerosis) (SSc) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report both the diagnosed incidence and the diagnosed prevalence of SSc for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting diagnosed incident and diagnosed prevalent patient populations, we estimate the number of drug-treatment opportunities in the major mature pharmaceutical markets.

DRG Epidemiology’s SSc forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with SSc?
  • Of all people diagnosed with SSc, how many in the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SSc over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In total, DRG Epidemiology forecasts seven SSc patient populations, as follows:

  • Diagnosed prevalent cases.
  • Diagnosed diffuse cutaneous prevalent cases.
  • Diagnosed limited cutaneous prevalent cases.
  • Diagnosed limited / unspecified prevalent cases.
  • Drug-treated prevalent cases.
  • Non-drug-treated prevalent cases.
  • Diagnosed incident cases.

Note: Coverage may vary by country.

Table of contents

  • Scleroderma (Systemic Sclerosis) - Epidemiology - Emerging Markets

Author(s): Sunali D. Goonesekera, SM

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.

Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.

Related Reports

Scleroderma (Systemic Sclerosis) - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard

Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees o...

View Details

Scleroderma (Systemic Sclerosis) - Unmet Need - Detailed, Expanded Analysis (US & EU)

The systemic sclerosis (SSc) pipeline is replete with therapies targeting pathways underlying autoimmunity, inflammation, and fibrosis, particularly in...

View Details

Scleroderma (Systemic Sclerosis) - Landscape & Forecast - Disease Landscape & Forecast

Systemic sclerosis (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifest...

View Details